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ABSTRACT
The efﬁcacy of albendazole for the treatment of giardiasis has been indicated by previous in-vitro and
in-vivo studies. In order to compare the therapeutic efﬁcacy of albendazole and metronidazole, 107
Giardia-positive children (aged 3–15 years), diagnosed by three consecutive positive stool examinations,
were enrolled in the study. Of these children, 52 were given a single daily dose of albendazole 10 mg ⁄ kg
for 5 days, and 55 were given metronidazole 20 mg ⁄kg daily in three doses for 7 days. Parasite
eradication was achieved in 47 (90.4%) of 52 children treated with albendazole and 49 (89.1%) of 55
children treated with metronidazole (p > 0.05). These results suggest that albendazole is an effective
treatment option for childhood giardiasis.
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INTRODUCTION
Giardia lamblia is a binucleate protozoan of the
Mastigophora sub-phylum that parasitises the
small intestines of mammals and causes intestinal
infection [1]. This parasitic disease, known as
giardiasis, is considered one of the most common
causes of diarrhoea in the world today [2].
Giardiasis is endemic in areas of poor sanitation
and is an important cause of morbidity in the
developing world, where it is associated with
infections in urban child care centres and resi-
dential institutions, as well as water- and food-
borne outbreaks [3]. Although giardiasis affects
mostly children, it can also occur in adults of any
age [4]. The prevalence among children world-
wide varies from 4% to 42%, but results from
many surveys may be artiﬁcially low following
examination of only one stool specimen [5].
Transmission of Giardia is common in certain
high-risk groups, including children and employ-
ees in child care centres, consumers of contamin-
ated water, travellers to certain areas of the world,
male homosexuals, and persons exposed to cer-
tain animals [3]. The clinical manifestations of
G. lamblia infection range from asymptomatic
carriage to a transient or persistent acute stage,
with steatorrhoea, intermittent diarrhoea and
weight loss, or to a sub-acute or chronic stage
that can mimic peptic ulcer disease [4].
Three major drug classes are of proven beneﬁt
in the treatment of giardiasis: the nitroimidazole
derivatives, acridine dyes such as mepacrine, and
the nitrofurans such as furazolidone [6]. The
nitroimidazoles, metronidazole and tinidazole,
are normally the drugs of choice, and are >90%
effective. Furazolidone (c. 80% effective) is often
used in children. None of these therapeutic
alternatives is clearly safe for use in pregnancy;
therefore, the poorly absorbed oral aminoglyco-
side paromomycin has been suggested for use in
this clinical situation.
Limited clinical data have suggested that the
anti-helminthic compound albendazole has anti-
giardial activity, and its efﬁcacy has been dem-
onstrated in several in-vivo and in-vitro studies.
In giardiasis, albendazole may act through tubu-
lins and giardins located in the cell skeleton of
G. lamblia. In addition, it has been shown that
albendazole inhibits the growth of G. lamblia
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trophozoites and their adhesion to intestinal
epithelial cells in vitro. The mechanism of this
activity is damage to microtubule and microrib-
bon function on the sucking discs of trophozoites
[7].
Treatment failures may occur with any of the
above therapies, consistent with in-vivo and in-
vitro data suggesting that strain-dependent drug
resistance not only exists, but may be induced
during the course of therapy [8]. In addition,
the widespread use of nitroimidazoles against
Giardia in children in the highly endemic areas
has been limited by poor patient compliance
associated with the unpalatability of the drugs,
varying sensitivity between Giardia isolates, and
the potential carcinogenic effects of these
compounds [8]. Thus, recent evidence for the
anti-giardial activity of albendazole raises the
prospect of safe and effective treatment of
children in endemic areas if the drug is used
with complementary health and hygiene educa-
tion programmes [7].
MATERIALS AND METHODS
Cases
In total, 655 children, aged 3–15 years, were studied. These
children were admitted to the Paediatrics Clinic of Celal Bayar
University Hospital with gastrointestinal complaints, inclu-
ding diarrhoea, weight loss, anorexia and fatigue, and were
examined for giardiasis between February and December 2002.
Stool samples were assessed for giardiasis by the saline–Lugol,
formalin ethyl acetate concentration and trichrome staining
methods [4]. Of the 655 children, 107 (16.3%) were positive for
G. lamblia cysts and ⁄ or trophozoites, and were treated accord-
ing to the study protocols.
Study protocols
The approval of the Ethics Committee of Celal Bayar Univer-
sity Medical School was obtained before the start of the study.
All parents were informed and their written consent was
obtained. The study group of 107 children with giardiasis
determined clinically and parasitologically (71 asymptomatic
and 36 symptomatic at that time) was divided into two
random groups. In group I, 52 children were given single-dose
albendazole tablets 10 mg ⁄ kg for 5 days. In group II, 55
children were given metronidazole in tablet or liquid form
20 mg ⁄kg daily in three doses for 7 days. Albendazole and
metronidazole are approved by the Ministry of Health in
Turkey.
All children completed their treatment regimens. To
evaluate the effectiveness of the therapy, stool samples from
all cases were examined on the 7th, 10th and 14th days
following completion of treatment by the same methods
and the same microscopist. Clinical symptoms were also
evaluated.
Statistical analysis
The data were evaluated by SPSS for Windows 6.1 (SPSS Inc.,
Chicago, IL, USA) and EPI Info 6.04b (WHO, Geneva,
Switzerland). Differences between the ratios in qualitative
variables were evaluated by Yates’ corrected chi-square test
(Fisher’s absolute veriﬁed test in the presence of frequencies
< 5). Differences with p < 0.05 were considered to be
statistically signiﬁcant.
RESULTS
In the overall study group, 64 (59.8%) children
had diarrhoea and 87 (81.3%) had symptoms such
as abdominal pain, anorexia, pruritis and foul-
smelling greasy stools. The demographic and
clinical features of treatment groups I and II are
summarised in Table 1.
Eradication of the parasites (i.e., no G. lamblia
cysts and ⁄ or trophozoites present) was achieved
in 49 (89.1%) of 55 children treated with
metronidazole, and 47 (90.4%) of 52 children
treated with albendazole (Table 2). There was no
statistically signiﬁcant difference between alben-
dazole treatment and metronidazole treatment
(p > 0.05).
Table 1. General and clinical features of children with
giardiasis in the two treatment groups
Group I
Albendazole
10 mg/kg/day
(n = 52)
Group II
Metronidazole
20 mg/kg/day
(n = 55)
Age in years
Mean 8.3 8.2
SD (range) 3.4 (3–15) 3.3 (3–15)
Sex
Male 28 (52%) 23 (42%)
Female 24 (48%) 32 (58%)
Weight (kg)
Mean 26.1 25.8
SD (range) 10.7 (12–61) 11.7 (16–59)
Stool frequencies
£ 10 stools ⁄day 15 (29%) 15 (27%)
> 10 stools ⁄day 37 (71%) 40 (73%)
Diarrhoea 30 (58%) 34 (62%)
Abdominal symptoms 44 (85%) 43 (79%)
Table 2. Parasite eradication following treatment with
albendazole or metronidazole
Number of parasite-free patients
Group I
Albendazole
(n = 52)
Group II
Metronidazole
(n = 55)
pDay 7 Day 10 Day 14 Day 7 Day 10 Day 14
30 (57.7%) 46 (88.5%) 47 (90.4%) 14 (25.5%) 28 (50.9%) 49 (89.1%) 0.92
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Clinical symptoms disappeared in all parasite-
free patients after treatment, and no side effects
were reported for either albendazole or metroni-
dazole during therapy.
DISCUSSION
The mainstay of treatment of giardiasis is metroni-
dazole, but other treatment options are required
because of occasional resistance. Metronidazole-
resistant Giardia strains have been isolated from a
numberof patientswho failed to respond tonormal
doses of metronidazole. Metronidazole is used
extensively worldwide, not only for giardia infec-
tions but also for the treatment of Trichomonas
vaginalis, Entamoeba histolytica, anaerobic bacteria
and protozoa, and for pre- and post-surgical pro-
phylaxis. Inappropriate dosing, poor compliance
and other factors that may expose Giardia to doses
of metronidazole of < 500 mg ⁄day have been
identiﬁed as potential factors that will facilitate
the development of resistance in Giardia. A combi-
nation of metronidazole and quinacrine appears to
bemore effective than eitherdrug alone for treating
resistant giardia infections [8]; however, quina-
crine is no longer manufactured in the USA.
Knowledge of the activity of other anti-giardial
compounds relies mostly on clinical experience,
as the routine reproduction, isolation and sus-
ceptibility testing of G. lamblia is difﬁcult. In-vivo
albendazole treatment of giardiasis has yielded
variable results. Thus, while albendazole 400 mg
was 95–97% effective when given as a single
daily dose for 5 days to children with giardiasis,
it was not effective in tourists returning from the
tropics [9–11]. Similarly, albendazole was effect-
ive in only 50% of schoolchildren with giardiasis
in Thailand [12]. In a study in Maryland, USA,
resistance against albendazole developed easily
in vitro [13]. Similarly, according to an Australian
study, G. lamblia developed resistance easily
against albendazole following modiﬁcations to
the cell structure of G. lamblia [14]. Although
more active benzimidazole derivatives have been
tested recently [15], albendazole remains on the
market as an alternative agent. In the present
study, the therapeutic efﬁcacy of albendazole
was slightly higher (90.4%) than that of a
conventional anti-giardial metronidazole regimen
(89.1%). Since there was no signiﬁcant difference
between these two agents in terms of treatment
efﬁcacy, side effects and treatment procedure, it
was concluded that albendazole was an effect-
ive and safe treatment choice for giardiasis in
Turkey, particularly if used with complementary
health and hygiene education programmes in
endemic areas.
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